Retinoid acid inhibits IL-1-induced iNOS, COX-2 and chemokine production in human chondrocytes.
This study aims to investigate the effects and mechanisms of all-trans retinoic acid (t-RA) on interleukin(IL)-1-induced production of several inflammatory mediators in human chondrocytes. The cartilage from OA patients receiving total knee or total hip replacement was obtained and chondrocytes were prepared. Chemokine concentrations were measured by ELISA. The expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) was determined by Western blotting and/or RT/PCR. Nitrite levels were measured by Griess assays. The DNA-binding activity and transcriptional activity of activator protein-1 (AP-1) were measured by electrophoresis mobility shift assay and luciferase assay. We showed that t-RA suppressed IL-1-induced release of chemokines, including regulated upon activation, normal T cell expressed and secreted (RANTES), monocyte chemoattractant protein 2 (MCP-2), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta. Four different retinoid derivatives all preserved inhibitory effects albeit the potency was different. t-RA potently suppressed IL-1-induced expression of iNOS and COX-2 and production of nitric oxide and prostaglandin E(2). In consistent with the results in primary chondrocytes, t-RA down-regulated IL-1-induced AP-1 DNA binding activity and transcriptional activity in a human fibroblast-like (commercially labeled as chondrocyte) cell line. By examining the effect of a c-jun N-terminal kinase (JNK) specific inhibitor, we showed that the suppression of JNK-AP-1 signaling was enough to inhibit IL-1-induced production of chemokines and activation of iNOS and COX-2 pathways. Collectively, our results raise a therapeutic option that intra-articular administration of retinoid derivatives at 10-1000 nanomolar concentrations may be effective to suppress the progression of inflammatory OA.
Hung
Li-Feng
LF
Division of Gerontology Research, National Health Research Institute, Taipei, Taiwan, ROC.
Lai
Jenn-Haung
JH
Lin
Leou-Chyr
LC
Wang
Shyu-Jye
SJ
Hou
Tsung-Yun
TY
Chang
Deh-Ming
DM
Liang
Chun-Chin T
CC
Ho
Ling-Jun
LJ
D000873:Anthracenes / Q000494:pharmacology; D002460:Cell Line; D018925:Chemokines / Q000096:biosynthesis; D019902:Chondrocytes / Q000187:drug effects / Q000378:metabolism*; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D015232:Dinoprostone / Q000378:metabolism; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism*; D048670:MAP Kinase Kinase 4 / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism*; D018808:Transcription Factor AP-1 / Q000378:metabolism; D014212:Tretinoin / Q000494:pharmacology*
D000873:Anthracenes; D018925:Chemokines; D007375:Interleukin-1; D018808:Transcription Factor AP-1; C432165:pyrazolanthrone; D014212:Tretinoin; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D048670:MAP Kinase Kinase 4; D015232:Dinoprostone